Introduction The prevalence of multiple myeloma (MM) has gradually increased over the last
few decades in India due to growing population, better disease awareness, and improved …

Immunotherapy is changing the paradigm of multiple myeloma (MM) management and
daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for …

The treatment of multiple myeloma has evolved markedly in the last decade, but mortality
remains high, emphasizing the need for more effective therapies. Daratumumab, a fully …

Background The anti-CD38 monoclonal antibody daratumumab is approved as a single
agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who …

Intravenous daratumumab (DARZALEX®), a human monoclonal antibody targeting CD38, is
approved in the EU and USA for use in combination with bortezomib, thalidomide and …

Objective: To review the available data for the efficacy and safety of daratumumab in the
treatment of multiple myeloma (MM), both in the newly diagnosed and relapsed/refractory …

Objective To systematically evaluate the efficacy and safety of combination regimens
containing daratumumab in patients with multiple myeloma (MM). Methods A systematic …

Background: Daratumumab as a monoclonal antibody has shown promising results in the
treatment of relapsed/refractory multiple myeloma (RRMM). However, the efficacy and safety …

BACKGROUND The treatment of multiple myeloma has significantly progressed over the
past half-century. The purpose of this study was to perform a systematic review and meta …

Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable.
CD38 is a 46 kDa type II transmembrane glycoprotein that is highly expressed on myeloma …